Concert Pharmaceuticals will concentrate on advancing its internal pipeline of deuteriummodified compounds and its ongoing partnerships with the upfront fees the Lexington Massachusettsbased company e…
Celgene has put another brick in the wall of positive late-stage data for apremalist as a new therapy for psoriatic arthritis, building on its new drug application at the FDA.
Ben Fidler The past 15 months have turned into a partnership symphony for Concert Pharmaceuticals. On Monday, the Lexington, MA-based company snagged its latest collaborative partner, revealing that…
Concert Pharma CEO Roger Tung has reeled in his third collaboration deal in a little more than a year, inking a $300 million pact with Celgene to tweak cancer and anti-inflammatory drugs with its deut…
